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Coenzyme Q (CoQ), a redox-active lipid essential for
oxidative phosphorylation, is synthesized by virtually all cells,
but how eukaryotes make the universal CoQ head group
precursor 4-hydroxybenzoate (4-HB) from tyrosine is unknown. The ﬁrst and last steps of this pathway have been
deﬁned in Saccharomyces cerevisiae, but the intermediates
and enzymes involved in converting 4-hydroxyphenylpyruvate
(4-HPP) to 4-hydroxybenzaldehyde (4-HBz) have not been
described. Here, we interrogate this pathway with genetic
screens, targeted LC-MS, and chemical genetics. We identify
three redundant aminotransferases (Bna3, Bat2, and Aat2)
that support CoQ biosynthesis in the absence of the established pathway tyrosine aminotransferases, Aro8 and Aro9.
We use isotope labeling to identify bona ﬁde tyrosine catabolites, including 4-hydroxyphenylacetate (4-HPA) and
4-hydroxyphenyllactate (4-HPL). Additionally, we ﬁnd multiple compounds that rescue this pathway when exogenously
supplemented, most notably 4-hydroxyphenylacetaldehyde
(4-HPAA) and 4-hydroxymandelate (4-HMA). Finally, we
show that the Ehrlich pathway decarboxylase Aro10 is
dispensable for 4-HB production. These results deﬁne new
features of 4-HB synthesis in yeast, demonstrate the redundant nature of this pathway, and provide a foundation for
further study.

Coenzyme Q (ubiquinone or CoQ) is a ubiquitous redoxactive lipid that functions as an essential component of the
respiratory chain and acts as a potent lipophilic antioxidant
(1, 2). CoQ is also an important redox cofactor for diverse
processes, including pyrimidine synthesis and sulﬁde oxidation
(3, 4). Consistent with these crucial cellular roles, defects in
CoQ biosynthesis are associated with diverse human diseases,
including cerebellar ataxia, nephrotic syndrome, and encephalomyopathy (5). A complete understanding of CoQ
biosynthesis could aid clinical diagnoses for the many cases of
CoQ deﬁciency still lacking an established genetic basis (6).

Traditional methods including yeast complementation assays
have identiﬁed many of the necessary genes for CoQ biosynthesis, but multiple key steps remain uncharacterized (7).
4-Hydroxybenzoate (4-HB) is the universal precursor for
CoQ’s fully substituted benzoquinone head group from bacteria to mammals (8, 9). In Saccharomyces cerevisiae, paraaminobenzoic acid (pABA) can also serve as a head group
precursor (10, 11). pABA is synthesized from chorismate in
two steps catalyzed by Abz1 and Abz2 (12, 13). The pathway
for 4-HB production in eukaryotes has not been elucidated,
but the ﬁrst and last steps have been described recently. 4Hydroxyphenylpyruvate (4-HPP) is a requisite early precursor made from tyrosine through aminotransferases Aro8 and
Aro9 or de novo through the shikimate pathway (14). The last
step in the pathway is the oxidation of 4-hydroxbenzaldehyde
(4-HBz) to 4-HB, catalyzed by the broad-speciﬁcity aldehyde
dehydrogenase Hfd1 (14, 15). However, the intermediates and
enzymes involved in converting 4-HPP to 4-HBz are unidentiﬁed (Fig. 1A).
Established metabolic pathways provide hypotheses about
the tyrosine to 4-HB pathway. The Ehrlich pathway is a general
route to catabolize aromatic and branched-chain amino acids
(16) (Fig. S1). After Aro8 and Aro9 convert tyrosine to 4-HPP,
the aromatic α-keto acid decarboxylase Aro10 converts 4-HPP
to 4-hydroxyphenylacetaldehyde (4-HPAA) (17). 4-HPAA is
then reduced to tyrosol or oxidized to 4-hydroxyphenylacetate
(4-HPA) depending on cellular needs (16), but it is unclear
whether any of these intermediates contribute to 4-HB synthesis. Aspergillus niger readily converts 4-HPAA to 4-HB
through a series of oxidations and decarboxylations resembling the mandelate pathway, although the enzymes involved
are unidentiﬁed, and it is possible that S. cerevisiae converts 4HPAA in a similar fashion (18, 19). There is also recent evidence
for a nonoxidative route from 4-HPP to 4-HBz, as p-coumarate
was shown to be incorporated into CoQ in both yeast and human cells (20). It has been proposed that p-coumarate could be
hydrated and then cleaved by a carbon–carbon lyase to produce
4-HBz and acetate (14). Despite these promising hints, neither
the oxidative nor nonoxidative pathway has been explored in
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Figure 1. Redundant aminotransferases convert tyrosine to 4-HPP to support 4-HB synthesis. A, schematic of 4-HB synthesis in budding yeast.
B, respiratory growth rates of W303 wild-type (WT) and Δaro8Δaro9Δaro2 strains assayed in –pABA media containing 0.1% (w/v) glucose and 3% (w/v)
glycerol and supplemented with the indicated additives (mean ± SD, n = 3). C, CoQ6 levels from the indicated yeast strains grown in –pABA media
containing 0.1% (w/v) glucose and 3% (w/v) glycerol (mean ± SD, n = 3). D, light (12C) and heavy (13C9) 4-HPP levels from yeast grown in –pABA media
containing 0.1% (w/v) glucose and 3% (w/v) glycerol, supplemented with light (12C) or heavy (13C9) tyrosine (mean ± SD, n = 3). E, drop assay of Δaro8Δaro9
yeast transformed with the indicated plasmids and grown for 3 days on the indicated solid media. F, respiratory growth rates of the indicated yeast strains
assayed in –pABA media containing 0.1% (w/v) glucose and 3% (w/v) glycerol and supplemented with the indicated additives (mean ± SD, n = 3).

detail. Here, we set out to identify intermediates and enzymes
involved in converting tyrosine to 4-HB.

Results
Redundant tyrosine aminotransferase activity supports 4-HB
synthesis
To study the fate of 4-HPP in 4-HB synthesis, we constructed
a W303 Δaro8Δaro9Δaro2 strain as a negative control, hypothesizing that it would be unable to produce 4-HPP (Fig. 1A).
Respiratory growth was only moderately impaired in –pABA
glycerol media (Fig. 1B), and we observed only a moderate CoQ
deﬁciency (Fig. 1C), consistent with BY4741 Δaro8Δaro9Δaro2
(14). We asked how Δaro8Δaro9Δaro2 yeast can make CoQ,
given that both routes to 4-HPP synthesis (tyrosine aminotransferase and shikimate pathway) are presumably blocked. We
reasoned that there is either redundant tyrosine aminotransferase activity present in this strain or a 4-HPP-independent
route for 4-HB synthesis. To differentiate between these two
models, we measured 4-HPP production in Δaro8Δaro9Δaro2
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yeast. There was a small amount of 4-HPP made in this strain
(Fig. 1D), which is likely sufﬁcient to support 4-HB synthesis.
Yeast possesses 12 α-amino acid aminotransferases including
Aro8 and Aro9, and we hypothesized that the other ten of these
enzymes are the most likely candidates for redundant tyrosine
aminotransferase activity. Aminotransferases are typically able
to catalyze transamination in both directions (albeit with
different efﬁciencies), as demonstrated by the ability of both
Aro8 and Aro9 to interconvert tyrosine and 4-HPP. Therefore,
to test this hypothesis, we individually overexpressed all 12 αamino acid aminotransferases in an Δaro8Δaro9 strain, which is
auxotrophic for tyrosine because it cannot make enough de novo
tyrosine from 4-HPP to support protein synthesis (21). Only
Aro8, Aro9, Bna3, Bat2, and Aat2 were sufﬁcient to confer
tyrosine prototrophy, indicating that these enzymes can interconvert tyrosine and 4-HPP in vivo (Fig. 1E). Deleting Bna3,
Bat2, and Aat2 from the Δaro8Δaro9Δaro2 strain blocked respiratory growth, which was rescuable with 4-HB supplementation (Fig. 1F). The Δaro8Δaro9Δaro2Δbna3Δbat2 and
Δaro8Δaro9Δaro2Δaat2 strains are respiratory-competent,
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Figure 2. Forward-genetic screens consistently identify HFD1 as the
only gene required for 4-HB production. A, general schematic of forwardgenetic yeast screens for genes involved in 4-HB synthesis. B, summary of
mutants and identiﬁed mutations recovered from eight forward-genetic
screens.

Table 1
Details of forward-genetic screens

Because our extensive genetic screens did not identify new
pathway enzymes, we next set out to map the intermediates

Mutant

Targeted LC-MS identiﬁes tyrosine catabolites

Background strain

Rescue plate additive

Control growth
rate (mOD/min)

Control
growth s.d.

Rescue growth
rate (mOD/min)

Thus far, HFD1 is the only known gene required for converting 4-HPP to 4-HB (Fig. 1A). In an attempt to discover
other genes, we performed forward-genetic screens by mutagenizing yeast with ethyl methanesulfonate (EMS) and
isolating colonies requiring exogenous 4-HB for respiratory
growth in media lacking pABA (Fig. 2A). In total, we performed eight of these screens with various sensitized background strains that collectively yielded 15 mutant strains
deﬁcient in 4-HB synthesis (Fig. 2B; Table 1). Thirteen of these
mutants harbor missense mutations in HFD1, and two harbor
missense mutations in COQ2, which encodes a 4-HB polyprenyltransferase that functions downstream of 4-HB synthesis (22). Notably, both mutated Coq2 residues reside in its
putative 4-HB binding site (23), and therefore these mutant
strains likely require 4-HB supplementation to overcome
decreased 4-HB afﬁnity and catalytic efﬁciency. Our inability
to detect mutations in additional genes while consistently
recovering HFD1 suggests that other enzymes involved in 4HB synthesis are likely either essential for growth under our
screening conditions or perform a redundant function in the
pathway. This redundancy could arise from multiple enzymes
performing each step (like the aminotransferases above), the
existence of multiple distinct pathways, or both.
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suggesting that BNA3, BAT2, and AAT2 must all be deleted to
block CoQ synthesis. We also observed that 4-HB supplementation did not fully rescue Δaat2 strains, indicating that Aat2 is
required for normal respiratory growth independent of 4-HB
production. Altogether, these results establish that ﬁve aminotransferases—Aro8, Aro9, Bat2, Bna3, and Aat2—redundantly
convert tyrosine to 4-HPP in vivo and emphasize the minute
amount of 4-HPP production required for CoQ synthesis.
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between 4-HPP and 4-HBz by identifying tyrosine catabolites
and 4-HB precursors. To determine whether potential pathway
intermediates are bona ﬁde tyrosine catabolites, we supplemented yeast with heavy (13C-labeled) tyrosine, extracted
metabolites, and performed targeted liquid chromatography–
mass spectrometry (LC-MS). In wild-type (WT) yeast, we
observed multiple heavy-labeled compounds after supplementing with heavy tyrosine, some of which (e.g., 4-HPP, 4HBz, 4-HB) have already been linked to 4-HB synthesis
(Fig. 3A). Among the other catabolites we identiﬁed, the most
abundant were tyrosol, 4-hydroxyphenylacetate (4-HPA), and
4-hydroxyphenyllactate (4-HPL). Phenylalanine catabolites
phenylpyruvate (PP) and phenyllactate (PL) were not labeled,
consistent with the documented inability of yeast to interconvert tyrosine and phenylalanine (24) (Fig. 3A). We constructed a model of the tyrosine to 4-HB pathway using our
absolute quantiﬁcation data from WT yeast, highlighting the
low steady-state levels of 4-HBz and 4-HB compared with
earlier intermediates (Fig. 3B).

Respiratory deﬁciency decreases 4-HPP/4-HPL ratio
Next, we repeated this targeted LC-MS approach with
Δhfd1 yeast to see if any upstream intermediates accumulate in
this strain. 4-HB was heavily decreased, as expected, but we
noted an unexpected decrease in 4-HPP, 4-HPA, and 4-HBz
relative to WT yeast (Fig. 3C). A possible explanation for
these changes is the concomitant increase in 4-HPL abundance in Δhfd1. This altered 4-HPP/4-HPL ratio may be due
speciﬁcally to loss of Hfd1 or may be the result of general
respiratory deﬁciency. In the latter case, reducing 4-HPP to 4HPL could act as an electron sink to regenerate depleted
oxidized redox cofactors such as NAD+ in a manner analogous
to the reduction of pyruvate to lactate (25). To distinguish
between these possibilities, we performed targeted LC-MS on
Δhfd1 yeast, whose respiratory deﬁciency could be rescued
with pABA, and Δcoq2 yeast, a respiratory-deﬁcient control
(Fig. 3D). The 4-HPP/4-HPL ratio was sharply decreased in
Δcoq2 yeast, matching Δhfd1, and rescuing Δhfd1 respiratory
growth with pABA restored the 4-HPP/4-HPL ratio (Fig. 3E).

Figure 3. Targeted LC-MS identiﬁes tyrosine catabolites. A, LC-MS absolute quantiﬁcation of targeted light (12C) and heavy (13C) compounds from yeast
grown in –pABA media containing 0.1% (w/v) glucose and 3% (w/v) glycerol, supplemented with light (12C) or heavy (13C9) tyrosine (mean ± SD, n = 3).
B and C, schematic of tyrosine catabolites in WT (B) or Δhfd1 (C) yeast. Circle areas are proportional to extract concentrations for each compound.
D, respiratory growth rates of the indicated yeast strains assayed in-pABA media containing 0.1% (w/v) glucose and 3% (w/v) glycerol and supplemented
with the indicated additives (mean ± SD, n = 3). E and F, ratios of 4-HPP/4-HPL (E) or PP/PL (F) from the indicated yeast strains grown in -pABA media
containing 0.1% (w/v) glucose and 3% (w/v) glycerol.
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Similar results were observed with the analogous phenylalanine catabolites PP and PL, demonstrating that these changes
are not speciﬁc to tyrosine metabolism (Fig. 3F). These data
suggest that the perturbed 4-HPP/4-HPL ratio in Δhfd1 stems
from an indirect effect of respiratory deﬁciency rather than the
lack of Hfd1, explaining the counterintuitive observation that
upstream intermediates decrease in abundance in Δhfd1 yeast.
More broadly, this result suggests that 4-HPP and PP have
underappreciated roles in buffering the cellular redox state
during perturbed cellular respiration.
Proposed intermediates rescue yeast in vivo
Having identiﬁed intermediates derived from tyrosine, we
next asked which of these compounds can be converted to 4HB in vivo. Potential 4-HB precursors were added to Δaro8Δaro9Δaro2 yeast to determine whether they could rescue
this strain’s respiratory growth defect. Of the tested compounds, 4-HPAA and 4-hydroxymandelate (4-HMA) rescued
most strongly (Fig. 4A). Notably, 4-HPA and 4-HPL, compounds that were abundantly labeled in the targeted LC-MS
assay, did not rescue respiratory growth. We veriﬁed that 4HPAA and 4-HMA do not rescue Δhfd1 yeast, demonstrating that their conversion to 4-HB depends on Hfd1 activity and that there is no appreciable 4-HB contamination in
these compound stocks (Fig. 4B).
To further validate these ﬁndings, we performed rescue
experiments in a Coq6 “bypass” strain. Coq6 is an essential
enzyme in the CoQ biosynthesis pathway that hydroxylates the
CoQ precursor polyprenyl hydroxybenzoate (PPHB) at the C3
position. However, a strain containing an activity-dead Coq6

mutant (G386A, N388D) can be bypassed with a “pre-hydroxylated” 3,4-dihydroxybenzoate (3,4-diHB) (26). We tested
whether 3,4-dihydroxy analogs of various hypothesized 4-HB
precursors could also rescue the Coq6-dead strain. 3,4dihydroxyphenylacetaldehyde
(3,4-diHPAA)
and
3,4dihydroxymandelate (3,4-diHMA) rescued respiratory growth
while 3,4-dihydroxyphenylacetate (3,4-diHPA) did not,
consistent with the results with the 4-hydroxy compounds in
Δaro8Δaro9Δaro2 (Fig. 4C). Once again, Hfd1 was required
for conversion to 4-HB.
Paradoxically, the most abundant tyrosine catabolites
observed with targeted LC-MS (4-HPA and 4-HPL) did not
rescue our 4-HB-deﬁcient strains, while the compounds that
rescued best (4-HPAA and 4-HMA) were not observed and
veriﬁed as tyrosine catabolites (Fig. 4D). A possible explanation
is that compounds that we observe at steady state might be
rate-limiting or unproductive intermediates, while compounds
we do not observe might be converted too quickly to accumulate. Of note, we were unable to measure 4-HPAA in the
LC-MS assay, so it is unclear if a pool of 4-HPAA is present
in vivo.
Aro10 is dispensable for 4-HB synthesis
Multiple compounds including 4-HPAA, 4-HPA, and
4-HMA are likely positioned downstream of the Ehrlich
pathway aromatic α-keto acid decarboxylase Aro10 (Fig. 4D;
Fig. S1). To further examine whether these compounds
support 4-HB synthesis, we deleted Aro10 and the
potentially redundant decarboxylases Pdc5 and Pdc6 (27). The
Δaro10Δpdc5Δpdc6 strain had elevated levels of 4-HPP, the

Figure 4. Novel 4-HB precursors rescue respiratory growth of CoQ-deﬁcient yeast. A–C, respiratory growth rates of the indicated yeast strains assayed
in –pABA media containing 0.1% (w/v) glucose and 3% (w/v) glycerol and supplemented with the indicated additives (mean ± SD, n = 3). D, updated
schematic of 4-HB synthesis.
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putative substrate of Aro10 in tyrosine catabolism (Fig. 5A). 4HPL levels were similarly increased (Fig. 5B), supporting the
hypothesis that 4-HPL exists in an equilibrium with 4-HPP as
an electron sink. 4-HPA and tyrosol, intermediates likely
downstream of the Aro10 product 4-HPAA, were sharply
decreased but not eliminated, providing further evidence that
Aro10 decarboxylates 4-HPP to 4-HPAA in WT yeast (Fig. 5,
C and D). However, the effect of these knockouts on 4-HB
synthesis was minimal, as 4-HBz and 4-HB levels were unchanged or even increased (Fig. 5, E and F). This demonstrates
that Aro10 is dispensable for 4-HB synthesis and suggests that
either the smaller pool of 4-HPAA in Δaro10Δpdc5Δpdc6 is
sufﬁcient to make the same amount of 4-HB or that 4-HPAA
is simply not converted to 4-HB.
If 4-HPAA is converted to 4-HB, we reasoned that
Δaro8Δaro9Δaro2 yeast, which has decreased levels of 4-HPP
and downstream compounds, might be sensitive to Aro10
deletion. However, deleting Aro10 and Pdc5 from Δaro8Δaro9Δaro2 did not affect respiratory growth (Fig. 5G) or CoQ
levels (Fig. 5H). We also hypothesized that overexpressing
Aro10 in Δaro8Δaro9Δaro2 yeast might help or harm 4-HB
synthesis if 4-HPP conversion to 4-HPAA is productive or
unproductive, respectively. However, we observe no change in
respiratory growth (Fig. 5I) or CoQ levels (Fig. 5J) upon Aro10
overexpression. Overall, these results call into question the
recent claim that Aro10 is involved in 4-HBz synthesis in
S. cerevisiae (28, 29).

Discussion
Studies of genetic robustness in yeast suggest that, even
though only 10–20% of genes are essential, most genes are
involved in functions that can only be interrogated with
multiple genetic or environmental perturbations (30, 31). Our
results demonstrate that the yeast tyrosine-to-4-HB pathway

contains signiﬁcant redundancy and indicate that multiple
gene knockouts are required to ablate steps prior to Hfd1’s
conversion of 4-HBz to 4-HB. For example, the ﬁrst reaction in
the pathway, transamination of tyrosine to 4-HPP, is catalyzed
primarily by Aro8 and Aro9, but we observe that deleting these
two enzymes is not sufﬁcient to block this step. We determine
that three additional aminotransferases—Bat2, Bna3, and Aat2
—are sufﬁcient to perform this reaction in vivo and that
deletion all ﬁve of these enzymes is required to block 4-HPP
production from tyrosine. Thus, yeast α-amino acid aminotransferases have a broader substrate speciﬁcity than previously thought, as ﬁve of 12 of these enzymes accept tyrosine as
a substrate in vivo. The last step in the 4-HB synthesis pathway
is catalyzed by Hfd1, another broad-speciﬁcity enzyme whose
substrates range from small aromatic aldehydes (4-HBz in
CoQ synthesis) to long-chain fatty aldehydes (hexadecanal in
sphingolipid catabolism) (14, 15). These examples suggest that
other pathway enzymes might also have broad substrate
speciﬁcities, and we expect that the relatively low amount of 4HB required for respiratory growth means that even “side
activities” could sufﬁce.
We used two strategies to identify metabolic intermediates that
could be participating in 4-HB synthesis. First, we observed bona
ﬁde tyrosine catabolites with isotopic labeling, including 4-HPL,
4-HPA, and tyrosol. Second, we identiﬁed compounds that boost
respiratory growth when added exogenously, including 4-HPAA
and 4-HMA. Surprisingly, we found that the heavy tyrosine catabolites that accumulate in vivo do not match the compounds
that rescue yeast when supplemented. Further work will be
required to fully resolve this paradox, but it is possible that the
compounds that accumulate at steady state are simply “waste” or
“cul-de-sac” products. This notion is consistent with the putative
roles of tyrosol and 4-HPA as Ehrlich pathway end products (16)
and our hypothesis that 4-HPL exists in a separate equilibrium

Figure 5. Ehrlich pathway 4-HPP decarboxylase Aro10 is not required for 4-HB synthesis. A–F, relative levels of light (12C) and heavy (13C) compounds
from yeast grown in –pABA media containing 0.1% (w/v) glucose and 3% (w/v) glycerol, supplemented with light (12C) or heavy (13C9) tyrosine (mean ± SD,
n = 3). G, respiratory growth rates of the indicated yeast strains assayed in –pABA media containing 0.1% (w/v) glucose and 3% (w/v) glycerol and supplemented with the indicated additives (mean ± SD, n = 3). H, CoQ6 levels from the indicated yeast strains grown in –pABA media containing 0.1% (w/v)
glucose and 3% (w/v) glycerol (mean ± SD, n = 3). I, respiratory growth rates of the indicated yeast strains assayed in –pABA media containing 0.1% (w/v)
glucose and 3% (w/v) glycerol and supplemented with the indicated additives (mean ± SD, n = 3). J, CoQ6 levels from the indicated yeast strains grown in –
pABA, –Ura media containing 0.1% (w/v) glucose and 3% (w/v) glycerol (mean ± SD, n = 3).
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with 4-HPP. Regardless, assigning intermediates to this pathway
with certainty will require additional genetic or biochemical
evidence.
S. cerevisiae underwent an ancient whole-genome duplication (WGD) event that resulted in >1000 paralogous genes,
contributing to genetic robustness (32, 33). Therefore, it may
be beneﬁcial to study 4-HB synthesis in model organisms with
less genomic redundancy. To this end, work is underway in
our laboratory to study this pathway in yeast species that have
not undergone WGD. Pathways from phenylalanine to 4-HB
have been identiﬁed in plants, but these do not account for
the entirety of 4-HB synthesis in A. thaliana (34, 35). It will
also be important to study 4-HB synthesis in mammalian cells,
given the importance of CoQ to human health. 4-HB is present
in human blood at 2 μM (36), and it is unclear whether
different cell types produce their own 4-HB or obtain it from
the bloodstream. We have shown that the human aldehyde
dehydrogenase ALDH3A1 rescues CoQ synthesis in Δhfd1
yeast (15), but it is unknown whether human cells convert 4HBz to 4-HB.
In summary, we show that the S. cerevisiae 4-HB synthesis
pathway is robust to single genetic alterations. We demonstrate that deleting three additional enzymes is required to
block the transamination of tyrosine to 4-HPP in the absence
of established enzymes Aro8 and Aro9. We expect that the
subsequent steps are also redundant, and our isotopic labeling
and chemical genetics approaches nominate several new
metabolic intermediates that may aid in identifying the
responsible enzymes. From this work in yeast, we suggest that
unresolved cases of human CoQ deﬁciency could result from
mutations in cytosolic aminotransferases or oxidoreductases,
with or without assigned biochemical functions.

drop-out mix (US Biological), yeast nitrogen base (with
ammonium sulfate and without amino acids) (US Biological),
and the indicated carbon source. –pABA (and dropout) media
contained Complete Supplement Mixture (Formedium), Yeast
Nitrogen Base without amino acids and without pABA (Formedium), and the indicated carbon source. Rich media were
sterilized by autoclave (20 min exposure), and synthetic media
were sterilized by ﬁltration (0.22 μm pore size).
Respiratory growth assays
Individual colonies of S. cerevisiae were used to inoculate
pABA-limited media (2% w/v glucose, 100 nM pABA) starter
cultures, which were incubated for 24 h (30  C, 230 rpm).
Yeast were swapped into –pABA media with glucose (0.1%, w/
v), glycerol (3%, w/v), and MES (50 mM, pH 5.6) at an initial
density of 5 × 106 cells/ml with indicated additives. The cultures were incubated (30  C, 1140 rpm) in an Epoch2 plate
reader (BioTek) in a sterile 96-well polystyrene round-bottom
microwell plate (Thermo) with a Breathe-Easy cover seal
(Diversiﬁed Biotech). Optical density readings (A600) were
obtained every 10 min, and growth rates were calculated with
Gen5 v3.02.2 software (BioTek), excluding time points before
the diauxic shift and during stationary phase growth.
Drop assay
Individual colonies of yeast transformed with p415 GPD
constructs were used to inoculate starter cultures (–Leu,
–pABA, 2% w/v glucose, 1 μM pABA), which were incubated
overnight (30  C, 230 rpm). Cells were spun down (21,000g,
2 min) and resuspended in water. Serial dilutions of yeast (105,
104, 103, 102, or 10 cells) were dropped onto 1.5% w/v agar
plates (–Leu, 2% w/v glucose or –Tyr, –Leu, –pABA, 2% w/v
glucose, 1 μM pABA) and incubated (30  C, 3 days).

Experimental procedures
Yeast strains and cultures

Forward-genetic screens

S. cerevisiae haploid W303 (MATa his3 leu2 met15 trp1
ura3) and BY4742 (MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0)
yeast were used. Yeast deletion strains were generated using
standard homologous recombination or CRISPR-mediated
methods. For homologous recombination, open reading
frames were replaced with the KanMX6, HygMX6, or NatMX6
cassette as previously described (37). CRISPR-mediated deletions were performed as described (38, 39). 20-mer guide
sequences were designed with the ATUM CRISPR gRNA
design tool (https://www.atum.bio/eCommerce/cas9/input)
and cloned into pRCC-K, and 500 ng of the guide-inserted
pRCC-K was used per yeast transformation. Donor DNA
was 300 pmol of an 80-nt Ultramer consisting of 40 bp upstream and 40 bp downstream of the ORF (for scarless deletions) or 6 μg of PCR-ampliﬁed Longtine cassette with
ﬂanking homology 40 bp upstream and 40 bp downstream of
the ORF (for cassette-replacement deletions). Deletions were
conﬁrmed by a PCR assay or Sanger sequencing.
Rich media contained yeast extract (1% w/v, DOT Scientiﬁc),
peptone (2% w/v, DOT Scientiﬁc), and the indicated carbon
source. Synthetic complete (and dropout) media contained

Individual colonies of yeast were used to inoculate YEPD
starter cultures, which were incubated overnight. 1.0 × 108
cells were pelleted, washed once with sterile water, and
resuspended in 2.5 ml of 100 mM sodium phosphate buffer,
pH 7.0. Ethyl methanesulfonate (EMS) (80 μl) was added, and
cells were incubated (90 min, 30  C, 230 rpm). Cells were
washed thrice with sodium thiosulfate (5% w/v) to inactivate
EMS. Cells were resuspended in water, and 1.0 × 104 cells were
plated on pABA-limited (2% w/v glucose, 100 nM pABA)
plates. After 3 days, cells were replica-plated onto –pABA (3%
glycerol, w/v) plates with 0 μM or 10 μM 4-HB (Sigma), or
other rescue compounds if indicated in Table 1. Colonies that
grew on plates with rescue compound were picked into YEPD
overnight cultures and struck on YEPD plates, and respiratory
growth phenotypes were conﬁrmed with plate reader growth
assays (see above). Mutations were identiﬁed with Sanger
sequencing.
Plasmid cloning
Expression plasmids were cloned with standard restriction
enzyme cloning methods. ORF-speciﬁc primers were used to
J. Biol. Chem. (2021) 296 100643

7

Intermediates and redundancies in 4-HB synthesis
amplify genes from W303 yeast genomic DNA, amplicons
were ligated into digested p415 GPD plasmid (40), and ligation
products were transformed into E. coli DH5α chemically
competent cells (NEB). Plasmids were isolated from transformants, and Sanger sequencing was used to identify those
containing the correct insertion.
Targeted HPLC-ECD for yeast CoQ6
CoQ measurements were performed generally as described
(39). Individual colonies of S. cerevisiae were used to inoculate
pABA-limited media (2% w/v glucose, 100 nM pABA) starter
cultures, which were incubated for 24 h (30  C, 230 rpm).
Yeast was swapped into –pABA media with glucose (0.1%, w/
v) and glycerol (3%, w/v) and incubated for 24 h (30  C,
230 rpm). 1 × 108 cells were collected by centrifugation (4000g,
5 min), resuspended in 1 ml water, transferred to 1.5 ml screwcap tubes, and centrifuged (21,000g, 1 min). In total, 50 μl of
KCl (150 mM) and 100 μl of glass beads (0.5 mm; RPI) were
added; 600 μl of ice-cold methanol (with 1 μM CoQ8 internal
standard) was added, and samples were vortexed (10 min, 4

C). In total, 400 μl of petroleum ether was added to extract
lipids, and samples were vortexed (3 min, 4  C) and centrifuged (1000g, 3 min) to separate phases. The petroleum ether
(upper) layer was collected, and the extraction was repeated
with another round of petroleum ether (400 μl), vortexing
(3 min, 4  C), and centrifugation (1000g, 3 min). The petroleum ether layers were pooled and dried under argon. Lipids
were resuspended in 2-propanol (25 μl) and transferred to
amber glass vials (Sigma; QSertVial, 12 × 32 mm, 0.3 ml).
Sodium borohydride (1 μl of 10 mM in 2-propanol) was added
to reduce quinones, and samples were vortexed brieﬂy and
incubated (5–10 min). Methanol (24 μl) was added to remove
excess sodium borohydride, and samples were vortexed brieﬂy
and incubated (5–10 min). Samples were brieﬂy ﬂushed with
nitrogen gas.
Samples were analyzed by reverse-phase high-pressure
liquid chromatography with electrochemical detection
(HPLC-ECD) using a C18 column (Thermo Scientiﬁc, Betasil
C18, 100 × 2.1 mm, particle size 3 μm) at a ﬂow rate of
0.3 ml/min with a mobile phase of 75% methanol, 20%
2-propanol, and 5% ammonium acetate (1 M, pH 4.4). After
separation on the column, quinones were quantiﬁed on ECD
detector (Thermo Scientiﬁc ECD3000-RS) equipped with
6020RS omni Coulometric Guarding Cell "E1" and 6011RS
ultra Analytical Cell "E2" and "E3." To prevent premature
quinone oxidation, the E1 guarding electrode was set
to −200 mV. Measurements were made using the analytical E2
electrode operating at 600 mV after complete oxidation of the
quinone sample, and E3 electrode (600 mV) was used to
ensure that total signal was recorded on the E2 cell. For each
experiment, a CoQ6 standard in 2-propanol was also prepared
with sodium borohydride and methanol treatment, and
different volumes were injected to make a standard curve.
Quinones were quantiﬁed by integrating respective peaks
using the Chromeleon 7.2.10 software (Thermo) and
normalized to CoQ8 internal standard.
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Targeted LC-MS
Individual colonies of S. cerevisiae were used to inoculate
pABA-limited media (2% w/v glucose, 100 nM pABA) starter
cultures, which were incubated for 24 h (30  C, 230 rpm). 1.2 ×
107 cells were transferred to 60 ml of light (–pABA, 0.1% w/v
glucose, 3% w/v glycerol, 10 nM pABA) or heavy (–pABA, –
Tyr, 0.1% w/v glucose, 3% w/v glycerol, 10 nM pABA, 276 μM
13
C9,15N-Tyr) growth media and incubated for 24 h (30  C,
230 rpm). 5 × 108 cells were isolated by rapid vacuum ﬁltration
onto a nylon ﬁlter membrane (0.45 μm pore size, Millipore)
using a Glass Microanalysis Filter Holder (Millipore), brieﬂy
washed with phosphate buffered saline (3 ml), and immediately submerged into extraction solvent (ACN/MeOH/H2O
2:2:1 v/v/v, 1.5 ml, −20  C) containing internal standards
(100
nM
3-hydroxybenzoate
and
100
nM
3hydroxyphenylhydracrylate) in plastic screw-cap tubes. Tubes
with the extraction solvent, nylon ﬁlter, and yeast were stored
at −80  C prior to analysis.
Samples were vortexed for 30 s twice, and the nylon
membrane ﬁlters were removed with tweezers prior to
centrifuging (13,000g, 5 min, 4  C). Supernatants (1 ml) were
transferred to new 2 ml Eppendorf tubes with the addition of
an internal standard (m-coumaric acid) to 20 μM. Samples
were dried in a vacuum concentrator. Once dried, samples
were reconstituted in 100 μl H2O. 2 ml Eppendorf tubes
containing resuspended samples were vortexed 15 s prior to
transfer to autosampler glass inserts. Standards were prepared
from 25 or 50 mM stock solutions of each compound and
diluted to bracket the concentration range 800 to 0.391 μM
(for tyrosine), 500 to 0.244 μM (for phenylalanine), 100 to
0.049 μM (for 4-hydroxymandelic acid, 3-phenyllactic acid,
and tyrosol), and 8 to 0.004 μM (for remaining compounds)
with 12 1:1 dilution steps.
LC-MS/MS analyses were performed using a randomized
sample order. An Ultimate HPG-3400RS pump and WPS3000RS autosampler (Thermo Fisher) were mated to an
ACQUITY UPLC HSS T3 column (2.1 × 150 mm, 1.8 μm
particle diameter, Waters Corporation) with an ACQUITY
UPLC HSS T3 VanGuard Pre-Column (2.1 × 5 mm, 1.8 μm
particle diameter, Waters Corporation). The autosampler was
maintained at 4  C. Mobile phase A was 0.1% aqueous acetic
acid and mobile phase B was ACN. The column was heated to
35  C. Mobile phase B was increased from 0% to 25% over
12.5 min at a ﬂow rate of 0.4 ml/min and then increased to
80% over 1 min along with an increase in ﬂow rate to 0.5 ml/
min. Mobile phase B was held at 80% for 2 min before being
decreased to 0% over 1 min. Mobile phase B was held at 0%
for 6 min for column re-equilibration before next injection.
The LC system was coupled to a TSQ Quantiva Triple
Quadrupole mass spectrometer (Thermo Scientiﬁc) by a
heated ESI source. The ion transfer tube and vaporizer temperatures were kept at 350  C. Sheath Gas was set to 28 units,
Auxiliary Gas to 14 units, and Sweep Gas to 0 unit. Negative
and positive spray voltages were time-dependent and set to
3600V and 3800V respectively. For targeted analysis, the MS
was operated in single reaction monitoring (SRM) mode
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acquiring scheduled, targeted scans to quantify selected
compound transitions. At least one transition was used for
each compound. All transitions, collision energies, and RF
Lens voltages were previously optimized by infusion of each
compound. The retention time window for each compound
or groups of compounds was optimized from prior experiments. MS acquisition parameters were 0.7 FWHM resolution for Q1 and 1.2 FWHM for Q3, 0.6 s cycle time, 1.5
mTorr CID gas, and 20 s Chrom Filter.
LC-MS/MS data were analyzed as described (41). Raw ﬁles
were processed using Xcalibur Quan Browser (v4.0.50,
Thermo Scientiﬁc) with results exported and further processed
using Microsoft Excel 2010. Quantiﬁcation was achieved
through use of an external calibration curve constructed from
the analysis of aqueous standard mixtures. Signal was not
linear across the entire measured range for some compounds,
and so calibrants were selected to bracket all samples, when
possible, with a minimum of ﬁve calibrant levels. For highly
abundant compounds, more dilute samples were used for
quantiﬁcation to stay below the upper limit of the calibration
range.
Statistical analysis
All experiments were performed in at least biological triplicate, unless stated otherwise. In all cases, "mean" refers to
arithmetic mean, and "SD" refers to sample standard deviation.
Statistical analyses were performed using Microsoft Excel. In
all cases, n represents biological replicates of an experiment.
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All data are contained within the article.
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